Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for proton pump inhibitors
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Importance: Anticoagulant choice and proton pump inhibitor (PPI) cotherapycould affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment. Objectives: To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants (...) with and without PPIcotherapy, and to determine variation according to underlying gastrointestinal bleeding risk. Design, Setting, and Participants: Retrospective cohort study in Medicare beneficiaries between January 1, 2011, and September 30, 2015. Exposures: Apixaban, dabigatran, rivaroxaban, or warfarin with or without PPIcotherapy. Main Outcomes and Measures: Hospitalizations for upper gastrointestinal tract bleeding: adjusted incidence and risk difference (RD) per 10 000 person-years of anticoagulant
Core IM: 5 pearls on proton pump inhibitors Core IM: 5 Pearls on PPIs – ClinicalCorrelations Search Core IM: 5 Pearls on PPIsAugust29, 2018 Podcast: | Subscribe: | By Cary Blum MD, Marty Fried MD and Shreya P. Trivedi MD || Illustration by Michael Shen MD. Quiz yourself on the 5 Pearls we will be covering: What are associated adverse effects for patients are on long-term PPIs? (2:02) What are some strategies to get your patient off PPIs? (10:57) How do histamine-2 (H2) receptor antagonists (...) blockers work and how can it explain why H2 blockers might not be as effective as PPIs? (13:30) How should you educate patients to take PPIstoget the maximize benefit? (16:48) How do you manage ongoing symptoms in patients on PPIs? (21:41) Many thanks to Dr. Peter Stanich from the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State University Medical Center for peer-reviewing this podcast! Subscribe to CORE IM on any podcast app! Follow us on Facebook || Twitter || Instagram
Proton pump inhibitors Top results for proton pump inhibitors - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for proton pump inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection
Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults 29676433 2018 04 28 1532-5415 2018 Apr 20 Journal of the American Geriatrics Society J Am Geriatr Soc Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. 10.1111/jgs.15385 To estimate associations between long-term use of proton pump inhibitors (PPIs) andpneumonia incidence in older adults in primary care. Longitudinal analyses of electronic medical records. England (...) PARTICIPANTS: Individuals aged 60 and older in primary care receiving PPIsfor1 year or longer (N=75,050) and age- and sex-matched controls (N=75,050). Net hazard ratios for pneumonia incidence in Year 2 of treatment were estimated using the prior event rate ratio (PERR), which adjusts for pneumonia incidence differences before initiation of treatment. Inverse probability weighted models adjusted for 78 demographic, disease, medication, and healthcare usage measures. During the second year after
No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) 29122546 2018 04 07 1528-0012 154 4 2018 03 Gastroenterology Gastroenterology No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). 861-873.e6 S0016-5085(17)36330-8 10.1053/j.gastro.2017.10.042 Proton pump inhibitors (PPIs) are (...) commonly used medications. Recent studies reported an increased risk of acute myocardial infarction (MI) in PPIusersvs non-users. We evaluated MI risk associated with PPIscomparedwith histamine-2 receptor antagonists (H2RAs) in privately insured adults in the United States. Using administrative claims from commercial and Medicare Supplemental plans (2001-2014), we compared risk of MI in patients who started a new prescription for PPIsvsH2RAs. Enrollees were followed from their first prescription
Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis 29339434 2018 03 08 1524-4628 49 2 2018 02 Stroke Stroke Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. 312-318 10.1161/STROKEAHA.117.019166 Pharmacokinetic and prior studies on thienopyridine and proton pump inhibitors (PPI) coadministrationprovide conflicting data for cardiovascular outcomes, whereas (...) there is no established evidence on the association of concomitant use of PPIandthienopyridines with adverse cerebrovascular outcomes. We conducted a systematic review and meta-analysis of randomized controlled trials and cohort studies from inception to July 2017, reporting following outcomes among patients treated with thienopyridine and PPIversusthienopyridine alone (1) ischemic stroke, (2) combined ischemic or hemorrhagic stroke, (3) composite outcome of stroke, myocardial infarction (MI), and cardiovascular
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study 29089382 2017 12 18 2017 12 18 1468-3288 67 1 2018 Jan Gut Gut Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. 28-35 10.1136/gutjnl-2017-314605 Proton pump inhibitors (PPIs) isassociated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP (...) )-infected subjects. We determined the association between PPIsuseand gastric cancer (GC) among HP-infected subjects who had received HP therapy. This study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded
Proton pump inhibitors for functional dyspepsia. BACKGROUND: Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), hasbeen proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIsaregenerally considered safe and well tolerated, they have been associated with adverse events (...) , especially in the long term. For this reason, decisions on whether to initiate or continue PPItherapyshould be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPItherapyprovides symptomatic relief in FD. OBJECTIVES: To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial 28719592 2017 07 18 2017 09 15 2017 09 15 1572-0241 112 9 2017 Sep The American journal of gastroenterology Am. J. Gastroenterol. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More (...) Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. 1374-1381 10.1038/ajg.2017.195 Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard salvage treatment is suboptimal. The objective of this study is to compare the efficacy
No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease 28695906 2017 07 11 2017 07 11 1572-0241 2017 Jul 11 The American journal of gastroenterology Am. J. Gastroenterol. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. 10.1038/ajg.2017.196 The objective of the study was to investigate whether proton pump inhibitor (PPI) useis associated with an increased risk of clinically verified Alzheimer's disease (AD). A Finnish nationwide nested (...) case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case (N=282,858). Data were extracted from Finnish nationwide health-care registers. PPIusewas derived from purchases recorded in the Prescription register data since 1995 and modeled to drug use periods with PRE2DUP method. AD was the outcome measure. PPIusewas not associated
Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency 27890768 2016 11 28 2017 03 04 1528-0012 152 4 2017 Mar Gastroenterology Gastroenterology Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. 821-829.e1 S0016-5085(16)35392-6 10.1053/j.gastro.2016.11.023 Proton pump inhibitors (PPIs) andhistamine-2 receptor antagonists (H2RAs) suppress gastric acid production, which can inhibit iron absorption. However, few data exist regarding (...) . Associations were estimated using conditional logistic regression. Among cases, 2343 (3.0%) received a prior ≥2-year supply of PPIsand1063 (1.4%) received H2RAs (without PPIuse). Among controls, 3354 (0.9%) received a prior ≥2-year supply of PPIsand2247 (0.6%) H2RAs. Both ≥2 years of PPIs (adjustedodds ratio, 2.49; 95% confidence interval, 2.35-2.64) and ≥2 years of H2RAs (odds ratio, 1.58; 95% CI, 1.46-1.71) were associated with an increased subsequent risk for iron deficiency. Among PPIusers, the
Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drugs Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. Theevidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) withclopidogrel antiplatelet
[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIsisunwarranted in many cases. • It will take more than clinical tools and training
Proton Pump Inhibitors and Kidney Diseaseâ€”GI Upset for the Nephrologist? 28845467 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist? 297-301 10.1016/j.ekir.2017.01.005 Widely regarded as safe and effective, proton pump inhibitors (PPIs) areamong the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPIuseand adverse (...) events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPItherapyto the development of kidney disease, including early case reports of acute interstitial nephritis and subsequent large observational studies of acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). The majority of studies showed higher risk of kidney outcomes among persons prescribed PPImedications, with effect sizes that were slightly higher
Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) andassess whether unmeasured confounding explains this association. Design Cohort study and self controlled case series. Setting Clinical Practice Research Datalink (1990 to 2013) in UK. Participants Adult patients with a new prescription for a PPI (...) individuallymatched with controls. Main outcome measures Association of community acquired pneumonia with PPIprescriptionestimated by three methods: a multivariable Cox model comparing risk in PPIexposedpatients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPIprescription. Results 160 000 new PPIuserswere examined. The adjusted Cox regression showed a risk